Y Intercept Hong Kong Ltd Has $545,000 Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Y Intercept Hong Kong Ltd trimmed its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 52.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,525 shares of the biopharmaceutical company's stock after selling 7,126 shares during the period. Y Intercept Hong Kong Ltd's holdings in Intra-Cellular Therapies were worth $545,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of ITCI. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Intra-Cellular Therapies by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the biopharmaceutical company's stock valued at $280,000 after purchasing an additional 670 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Intra-Cellular Therapies by 185.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 8,810 shares of the biopharmaceutical company's stock valued at $645,000 after purchasing an additional 5,725 shares in the last quarter. US Bancorp DE increased its stake in Intra-Cellular Therapies by 3.3% in the 3rd quarter. US Bancorp DE now owns 7,951 shares of the biopharmaceutical company's stock valued at $582,000 after buying an additional 251 shares during the period. Emerald Mutual Fund Advisers Trust lifted its position in Intra-Cellular Therapies by 6.6% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 334,673 shares of the biopharmaceutical company's stock worth $24,488,000 after buying an additional 20,622 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its stake in shares of Intra-Cellular Therapies by 144.6% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 34,974 shares of the biopharmaceutical company's stock valued at $2,559,000 after buying an additional 20,676 shares during the period. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Trading Up 2.4 %

ITCI traded up $3.08 during trading on Monday, hitting $131.28. The stock had a trading volume of 7,155,386 shares, compared to its average volume of 3,931,705. The firm has a market cap of $13.96 billion, a PE ratio of -150.89 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a 12 month low of $63.30 and a 12 month high of $131.35. The company has a 50 day simple moving average of $114.58 and a 200-day simple moving average of $91.72.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Transactions at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the firm's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 2.60% of the company's stock.

Wall Street Analysts Forecast Growth

ITCI has been the topic of a number of research reports. StockNews.com started coverage on shares of Intra-Cellular Therapies in a research note on Monday, February 24th. They issued a "hold" rating on the stock. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their price target for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Royal Bank of Canada reissued a "sector perform" rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Baird R W lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.